Skip to main content

Erasca, Inc 8-K, filed Nov 20, 2026

Erasca, Inc. (ERAS)

8-K 2026-11-20 For: 2026-11-20
View Original
Added on November 20, 2026

About this 8-K

Erasca, Inc filed this 8-K on November 20, 2026.

Erasca's ERAS-0015 showed a 44% confirmed objective response rate across 25 patients with KRAS G12X mutations. The Phase 3 trial in first-line pancreatic cancer is accelerated to the first half of 2027. AI summary

Items reported

  • Item 8.01: Other events